Cutaneous lymphoproliferative disorders after COVID-19 vaccination : clinical presentation, histopathology, and outcomes
Individual reports described lymphoproliferative disorders (LPDs) after COVID-19 vaccination; however, the relationship between cases is unexamined. We aim to determine if there are cases of cutaneous LPDs associated with COVID-19 vaccination and their outcomes. We present a review of world literature, vaccine registries, and two unreported cases of LPDs after COVID-19 vaccination. Review of the medical literature, VAERS, and our two cases reveal predominance of Pfizer-BioNTech vaccine, younger patients, and males. All cases resulted in favorable outcomes. Approximately 84% of cases demonstrated CD30+ positivity in their skin biopsies, suggesting that an antigenic trigger may lead to a type IV adaptive immune response, with clonal expansion of CD30+ T-cells and subsequent oncogenic mutational hits eventuating in transient LPDs. LPDs after COVID-19 vaccination appear in the context of the same vaccines (proportionally to their global market shares), share clinical and pathological findings, and have indolent, self-limited character.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Leukemia & lymphoma - 65(2024), 1 vom: 12. Jan., Seite 48-54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gordon, Emily R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.01.2024 Date Revised 12.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10428194.2023.2270766 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363540644 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363540644 | ||
| 003 | DE-627 | ||
| 005 | 20240114234242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2023.2270766 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1257.xml |
| 035 | |a (DE-627)NLM363540644 | ||
| 035 | |a (NLM)37861685 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gordon, Emily R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cutaneous lymphoproliferative disorders after COVID-19 vaccination |b clinical presentation, histopathology, and outcomes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2024 | ||
| 500 | |a Date Revised 12.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Individual reports described lymphoproliferative disorders (LPDs) after COVID-19 vaccination; however, the relationship between cases is unexamined. We aim to determine if there are cases of cutaneous LPDs associated with COVID-19 vaccination and their outcomes. We present a review of world literature, vaccine registries, and two unreported cases of LPDs after COVID-19 vaccination. Review of the medical literature, VAERS, and our two cases reveal predominance of Pfizer-BioNTech vaccine, younger patients, and males. All cases resulted in favorable outcomes. Approximately 84% of cases demonstrated CD30+ positivity in their skin biopsies, suggesting that an antigenic trigger may lead to a type IV adaptive immune response, with clonal expansion of CD30+ T-cells and subsequent oncogenic mutational hits eventuating in transient LPDs. LPDs after COVID-19 vaccination appear in the context of the same vaccines (proportionally to their global market shares), share clinical and pathological findings, and have indolent, self-limited character | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD4+ small/medium sized pleomorphic T-cell lymphoproliferative disorder | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a Cutaneous lymphoproliferative disorder | |
| 650 | 4 | |a cutaneous lymphoma | |
| 650 | 4 | |a cutaneous reactions | |
| 650 | 4 | |a lymphomatoid papulosis | |
| 650 | 4 | |a vaccination reaction | |
| 650 | 4 | |a vaccine mechanism | |
| 650 | 4 | |a vaccine-associated lymphoproliferative disorder | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Ki-1 Antigen |2 NLM | |
| 700 | 1 | |a Kwinta, Bradley D |e verfasserin |4 aut | |
| 700 | 1 | |a Schreidah, Celine M |e verfasserin |4 aut | |
| 700 | 1 | |a Fahmy, Lauren M |e verfasserin |4 aut | |
| 700 | 1 | |a Adeuyan, Oluwaseyi |e verfasserin |4 aut | |
| 700 | 1 | |a Queen, Dawn |e verfasserin |4 aut | |
| 700 | 1 | |a Trager, Megan H |e verfasserin |4 aut | |
| 700 | 1 | |a Magro, Cynthia M |e verfasserin |4 aut | |
| 700 | 1 | |a Geskin, Larisa J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g 65(2024), 1 vom: 12. Jan., Seite 48-54 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2024 |g number:1 |g day:12 |g month:01 |g pages:48-54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2023.2270766 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2024 |e 1 |b 12 |c 01 |h 48-54 | ||